IJGC Podcast

Impact of TIVA on postoperative opioid consumption with Javier Lasala

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Javier Lasala to discuss the impact of TIVA on postoperative opioid consumption. Dr. Lasala is an Associate Professor of Anesthesiology at The University of Texas MD Anderson Cancer Center in Houston, TX. He is currently the Vice Chair of Clinical Affairs in his department and has been involved with Enhanced Recovery after Surgery pathways for the past 7 years. In addition he serves as the anesthesiology lead for the gynecologic oncology program and co-lead for the thoracic surgical program.
Highlights:
(1) Total intravenous anesthesia (TIVA) technique reduces the amount of post-operative opioid consumption in a well-established ERAS program.
(2) Multimodal analgesia in combination with high compliance to an ERAS program will decrease patient opioid utilization.
(3) Pain scores were unchanged with the decreased use of opioids in the post-operative course.
(4) Future analysis will look at the anesthesia technique and opioid utilization and the effect on patient reported outcomes.

Reviewing the May Issue with Anna Collins and Nicolò Bizzarri (English version)

In this episode of the IJGC Podcast, Editorial Fellows Anna Collins and Nicolo Bizzarri discuss the contents of the May issue of IJGC in English.

Reviewing the May Issue with Enrique Chacon (Spanish version)

In this episode of the IJGC Podcast, Editorial Fellow Enrique Chacon discuss the contents of the May issue of IJGC in Spanish.

SLN Mapping in Endometrial Cancer Consensus with Andreas Obermair

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Andreas Obermair to discuss SLN mapping in endometrial cancer consensus with Andreas Obermair. Dr. Obermair is the lead author on , “Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer” (https://ijgc.bmj.com/content/early/2021/03/31/ijgc-2020-002315), which is the Lead Article for the May 2021 issue of IJGC. Dr. Obermair is a gynaecological oncologist in Brisbane, Australia promoting surgery with proven better patient outcomes.

Reviewing the April Issue with Alex Mutombo (French Version)

In this episode of the IJGC Podcast, Editorial Fellow Alex Mutombo reviews the contents of the April issue in French.

Reviewing the April Issue with Nicolò Bizzarri (Italian Version)

In this episode of the IJGC Podcast, Editorial Fellow Nicolò Bizzarri discusses the contents of the April issue in Italian.

Recurrent Ovarian Cancer: SOC-1 Trial with Rongyu Zang and Tingyan Shi

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Rongyu Zang and Tingyan Shi to discuss recurrent ovarian cancer and the SOC-1 Trial.
Professor Zang is the Director of the Department of Gynecologic Oncology at Zhongshan Hospital, Fudan University in Shanghai, China. He has been specializing in gynecologic oncology, especially in clinical and translational research of advanced and recurrent ovarian cancer for the last two decades. As the founder of Shanghai Gynecologic Oncology Group (SGOG), he has been closely associated with the Gynecologic Cancer InterGroup since 2009. Professor Zang initiated several national and international multi-center randomised clinical trials, including the dose-dense EPIC trial and the SUNNY trial for advanced ovarian cancer, as well as the secondary cytoreduction trial for recurrent ovarian cancer, and so on.
Dr. Shi is an Associate Professor of Oncology in the Department of Gynecologic Oncology at Zhongshan Hospital, Fudan University in Shanghai, China. She has focused on clinical and translational research in gynecologic oncology for over ten years. Dr. Shi has been trained in the Young Investigator Program of Gynecologic Cancer InterGroup, and participated in several international and national multi-center randomized clinical trials for ovarian cancer.
Highlights
+ SOC-1 selected the candidates for secondary cytoreductive surgery with iMODEL score of 4.7 or less even after the correction by PET-CT imaging.
+ Secondary cytoreductive surgery favorably impacts platinum-sensitive relapsed ovarian cancer, but incomplete resection leads to the worst survival compare to no-surgery.
+ Accumulating treatment-free survival, as an important secondary endpoint, was added to explore the long-term survival benefit affected by a high proportion of cross-over from the no surgery froup to the surgery group when overall survival data are mature.
+ In both primary and recurrent settings of ovarian cancer, randomized trials are needed to confirm the survival benefit of complete surgery followed by targeting maintenance therapy.

Legends in Gynecologic Oncology with Charles Levenback

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Charles Levenback, who is being highlighted by IJGC as a legend in gynecologic oncology. Dr. Levenback completed his fellowship at Memorial Sloan Kettering Cancer center in 1989 and then practiced at MD Anderson for 31 years. He is known as a pioneer in the development of sentinel lymph node biopsy in Gynecologic oncology, master clinician, educator, and champion for quality and safety.
Highlights:
+ Career and professional development
+ Sentinel lymph node development from small case series to phase III national trial
+ Interest in quality improvement and patient safety

Reviewing the April Issue with Enrique Chacon (Spanish Version)

In this episode of the IJGC Podcast, Editorial Fellow Enrique Chacon discusses the contents of the April issue in Spanish.

The Mentors Podcast with Pedro Ramirez

In this episode of the IJGC Podcast, Editor-in-Chief Pedro Ramirez joins Editorial Fellows Anna Collins, Irina Tsibulak, Nicolò Bizzarri, Alex Mutombo, Enrique Chacon and Arthur Hsu for an extended discussion of their experiences in gynecologic oncology, the importance of mentorship, and pathways for development in the field.